Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
Rigel Pharmaceuticals (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer therapies, will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025.
The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss financial results and provide a business update. Investors can join via phone or access the webcast through Rigel's investor relations website, where it will remain available for replay for 90 days.
Rigel Pharmaceuticals (Nasdaq: RIGL), un'azienda biotecnologica specializzata in disturbi ematologici e terapie oncologiche, comunicherà i suoi risultati finanziari del secondo trimestre 2025 dopo la chiusura del mercato, martedì 5 agosto 2025.
L'azienda terrà una conference call e una diretta web alle 16:30 ora della costa orientale per discutere i risultati finanziari e fornire un aggiornamento sull'attività. Gli investitori potranno partecipare telefonicamente o seguire la diretta sul sito web delle relazioni con gli investitori di Rigel, dove sarà disponibile per la visione in differita per 90 giorni.
Rigel Pharmaceuticals (Nasdaq: RIGL), una compañía biotecnológica centrada en trastornos hematológicos y terapias contra el cáncer, presentará sus resultados financieros del segundo trimestre de 2025 después del cierre del mercado el martes 5 de agosto de 2025.
La empresa realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m., hora del Este para discutir los resultados financieros y ofrecer una actualización del negocio. Los inversores podrán unirse por teléfono o acceder a la transmisión a través del sitio web de relaciones con inversores de Rigel, donde estará disponible para reproducción durante 90 días.
Rigel Pharmaceuticals (나스닥: RIGL)는 혈액 질환 및 암 치료에 중점을 둔 생명공학 회사로, 2025년 2분기 재무 결과를 2025년 8월 5일 화요일 시장 마감 후에 발표할 예정입니다.
회사는 동부 표준시 오후 4시 30분에 재무 결과를 논의하고 사업 현황을 업데이트하기 위한 컨퍼런스 콜과 웹캐스트를 진행합니다. 투자자는 전화로 참여하거나 Rigel 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 해당 웹캐스트는 90일 동안 다시보기로 제공됩니다.
Rigel Pharmaceuticals (Nasdaq : RIGL), une entreprise biotechnologique spécialisée dans les troubles hématologiques et les thérapies contre le cancer, publiera ses résultats financiers du deuxième trimestre 2025 après la clôture du marché le mardi 5 août 2025.
L'entreprise organisera une conférence téléphonique et une diffusion en direct à 16h30, heure de l'Est pour discuter des résultats financiers et fournir une mise à jour commerciale. Les investisseurs pourront participer par téléphone ou accéder au webcast via le site des relations investisseurs de Rigel, où il restera disponible en replay pendant 90 jours.
Rigel Pharmaceuticals (Nasdaq: RIGL), ein Biotechnologieunternehmen mit Fokus auf hämatologische Erkrankungen und Krebstherapien, wird seine Finanzergebnisse für das zweite Quartal 2025 nach Börsenschluss am Dienstag, den 5. August 2025 bekanntgeben.
Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können telefonisch teilnehmen oder den Webcast über die Investor-Relations-Website von Rigel verfolgen, wo er für 90 Tage als Aufzeichnung verfügbar bleibt.
- None.
- None.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2025-financial-results-and-business-update-302515528.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
When will Rigel Pharmaceuticals (RIGL) report Q2 2025 earnings?
How can investors access Rigel's Q2 2025 earnings call?
What time is Rigel's Q2 2025 earnings call?
How long will Rigel's Q2 2025 earnings webcast be available for replay?
What is Rigel Pharmaceuticals' main business focus?
